AstraZeneca’s Ardea Purchase May Be First of New Deals

AstraZeneca’s $1.26 billion purchase of Ardea Biosciences, the biggest acquisition in five years, may be the first in a series of deals for the company as it tries to counter looming generic competition.
Bloomberg